-
Product Insights
Recurrent Glioblastoma Multiforme (GBM) – Drugs In Development, 2023
Global Markets Direct’s, ‘Recurrent Glioblastoma Multiforme (GBM) - Drugs In Development, 2023’, provides an overview of the Recurrent Glioblastoma Multiforme (GBM) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Recurrent Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Transitional Cell Carcinoma (Urothelial Cell Carcinoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Transitional Cell Carcinoma (Urothelial Cell Carcinoma) - Drugs In Development, 2023’, provides an overview of the Transitional Cell Carcinoma (Urothelial Cell Carcinoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Transitional Cell Carcinoma (Urothelial Cell Carcinoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development...
-
Product Insights
Osteoporosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Osteoporosis - Drugs In Development, 2023’, provides an overview of the Osteoporosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Osteoporosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Atypical Hemolytic Uremic Syndrome (Nondiarrhea – Associated Hemolytic Uremic Syndrome) – Drugs In Development, 2023
Global Markets Direct’s, ‘Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) - Drugs In Development, 2023’, provides an overview of the Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Atypical Hemolytic Uremic Syndrome (Nondiarrhea - Associated Hemolytic Uremic Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers...
-
Product Insights
Cytokine Release Syndrome (Cytokine Storm) – Drugs In Development, 2023
Global Markets Direct’s, ‘Cytokine Release Syndrome (Cytokine Storm) - Drugs In Development, 2023’, provides an overview of the Cytokine Release Syndrome (Cytokine Storm) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Cytokine Release Syndrome (Cytokine Storm), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Macular Edema – Drugs In Development, 2023
Global Markets Direct’s, ‘Macular Edema - Drugs In Development, 2023’, provides an overview of the Macular Edema pipeline landscape. The report provides comprehensive information on the therapeutics under development for Macular Edema, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Hemolytic Uremic Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemolytic Uremic Syndrome - Drugs In Development, 2023’, provides an overview of the Hemolytic Uremic Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemolytic Uremic Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Prestige Group – Prestige Serenity Shores Residential Complex – Karnataka
The Prestige Group – Prestige Serenity Shores Residential Complex – Karnataka project involves the construction of four residential towers comprising 657 units in Bengaluru, Karnataka, India. Equip yourself with the essential tools needed to make informed and profitable decisions with our Prestige Group – Prestige Serenity Shores Residential Complex – Karnataka report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding weekends...
-
Product Insights
Saigon Trading – Okura Prestige Saigon Hotel Tower – Ho Chi Minh City
The Okura Prestige Saigon project involves the construction of a 30,000m2 40-story five-star hotel tower comprising 250 rooms in Ho Chi Minh City, Vietnam. Equip yourself with the essential tools needed to make informed and profitable decisions with our Saigon Trading – Okura Prestige Saigon Hotel Tower – Ho Chi Minh City report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business days of the purchase, excluding...
-
Product Insights
Prestige Group – Prestige Aston Park Residential Complex – Karnataka
The Prestige Group – Prestige Aston Park Residential Complex – Karnataka project involves the construction of two, 27-story and three 26-story towers comprising 701 units on 1.61ha of land in Bengaluru, Karnataka, India. Equip yourself with the essential tools needed to make informed and profitable decisions with our Prestige Group – Prestige Aston Park Residential Complex – Karnataka report. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3...